Real-world evidence (RWE) shows that HIV-associated wasting (HIVAW) remains a significant comorbidity
12 April 2022
- A first retrospective, RWE study investigating HIVAW in more than 10 years suggests the condition remains a significant comorbidity despite modern antiretroviral therapy (ART).
- Results showed the overall prevalence of HIVAW in the study of 42,587 HIV+ patients was 18.3%.
- “Many physicians consider HIV-associated wasting no longer an existing comorbidity in the era of modern ART, but the evidence suggests otherwise and the continued need for on-going assessments of people living with HIV for weight loss,”
Chief Medical Officer of TeleMed2UClick here to learn more.